Active Energy Group (LON:AEG) (AEG, 5.125p, £5.75m) Interims to June 2010 from the old Cinpart Plc (LON:CINP) group saw revenues soar to £2.80m (£0.80m) with gross profits of £0.58m (£0.25m), gross margins of 21% (30.65%) though higher admin expenses of £1.21m (£0.95m) limited the reduction in op losses with £0.63m (£0.70m) and a PBT loss of £0.63m (£0.71m). The group ended the period with period end net cash of £0.06m (£0.82m) reflecting £0.65m used in operations and has since the period end has raised £1.39m – giving is sufficient cash. We see a second half of further contract news, given the relationships established in H1 that include Scottish & Southern and the County Executives of America. The group saw a recovery in its traditional businesses of Gasignition (UK based) and Derlite (Thailand) with revenues of £1.14m (£0.80m) with the Active Energy contributing a maiden £1.66m of sales. We see a second half of further contract news, given the relationships established in H1 that include Scottish & Southern and the County Executives of America, indeed the group has highlighted it has trial installations in a number of large organisations. SPECULATIVE BUY  

Deltex Medical Group (LON:DEMG) (DEMG, 9.75p, £12.66m) the global leader in oesophageal Doppler Monitoring reports interims to 30 June 2010. Growth in revenues by 13% across all areas (UK, USA and Spain) has led to sales of £2.9 (H109: £2.6m) and reduced pre-tax losses to £0.66m (H109: £1.19m). Net debt came in higher than expected at £1.29m (FY09: £0.35m). Management believe the group is strongly positioned to benefit from the UK policy initiatives aimed at delivering better quality care at lower cost through the introduction of innovative evidence-based technologies. Deltex has been informed that such initiatives have been endorsed by the UK's new coalition government. However, we believe there could be a time lag with investment decisions being delayed. We are encouraged by the statement. Sales growth and tight cost control should result in the group achieving cash neutrality in H2 2011. We reiterate our SPECULATIVE BUY recommendation with a target price of 11.5p.  

Imaginatik Plc (LON:IMTK) (IMTK, 2.38p, £5.05m), has secured an annual contract renewal and extension with…

Unlock the rest of this article with a 14 day trial

Unlock with Email
Unlock with Google

Already have an account?
Login here